Briefing
Molecular residual disease (MRD) detection with a tissue comprehensive genomic profiling (CGP)-informed personalized monitoring assay: An exploratory analysis of the IMvigor-010 observation arm.
ctDNA was detected at the MRD timepoint in 66/182 (36%). Of those 66, 58 (88% PPV) had relapsed at analysis. Median DFS from randomization was 3 months if ctDNA-positive versus not reached if negative (HR 5.7, 95% CI 3.8-8.6); median OS 13 months vs not reached (HR 5.7, 95% CI 3.4-9.7).
- n: 182 patients on the observation arm evaluated at the MRD timepoint
- Assay: tissue comprehensive genomic profiling-informed personalized monitoring assay (Foundation Medicine approach, as described in the abstract)